Monogram And Dana-Farber Cancer Institute Initiate Evaluation Of HERmark(TM) Breast C
Monogram Biosciences, Inc. (Nasdaq: MGRM) announced that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer.
More... |
All times are GMT -7. The time now is 07:01 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021